AbbVie Ventures

AbbVie Ventures is the corporate venture arm of AbbVie, the global biopharmaceutical company behind Humira, Skyrizi, and the Allergan aesthetics franchise. As a strategic CVC tied to a top-tier pharma, the fund’s posture is fundamentally different from financial VCs: investments are made to inform AbbVie’s pipeline, build optionality on next-generation modalities, and create commercial or partnership pathways. The mandate skews toward therapeutics — immunology, oncology, neuroscience, and eye care reflecting AbbVie’s TA priorities — with selective interest in enabling platforms such as AI-driven drug discovery, novel delivery, and translational tools that materially compress development timelines. Stage is typically Series A through C, with check sizes commensurate with a multinational pharma CVC, plausibly $5M to $25M and capacity to follow on in larger syndicates led by tier-one biotech VCs. AbbVie Ventures is the right partner for founders who want a pharma on the cap table for credibility, regulatory know-how, and a real shot at a partnership or acquisition outcome. Founders should approach if you have validated science, a credible IP position, and a program that maps to AbbVie’s therapeutic priorities; you should not approach if you are pre-clinical with no in vivo data, building pure-software clinical workflow tools, or working in TAs AbbVie does not pursue. Be aware of strategic considerations: cap table optics, information rights, and competitive sensitivities can complicate downstream rounds. Entry path is through the AbbVie partnering organization, a tier-one biotech VC co-investor, or scientific KOLs already engaged with AbbVie.